Lessons Learned During the SARS-CoV-2 Pandemic

121st Meeting of the Advisory Committee to the Director (ACD)
National Institutes of Health

Lawrence A. Tabak, DDS, PhD
Principal Deputy Director, NIH
Department of Health and Human Services
observations
People

- Paramount concern for the health and safety of NIH staff and extramural workforce
  - How best to ensure:
    - Work/life balance
    - Mental health
    - Dependent Care
    - Safe return to Work
  - Concerns of professional women are much more serious than some had previously appreciated
- Enhancing work flexibility for NIH staff and increasing empathy towards those with challenges -> creative, timely results!
  - Once again, NIH staff rose to the occasion!
- Have attempted to provide maximum flexibility to extramural workforce
Innovation

• Extraordinary value in working with Industry, FNIH, other USG entities (ACTIV; OWS) – can these partnerships be maintained going forward or is a crisis required?

• Does the RADx *Innovation Funnel* represent a new model for SBIR/STTR? For other awards?
  • Opening opportunities for new players
  • Stress forces “early failure”

• The importance and value of IRP when a rapid scientific response is needed was underscored
  • Vaccine Research Center (VRC) - the investigational COVID-19 vaccine, mRNA-1273, was co-developed by the biotechnology company Moderna, Cambridge, MA, and the VRC in NIAID/NIH
NIH Clinical Trials

• Unprecedented response by NIH to a global crisis
  • But also revealed some of the challenges of activating academic centers; CROs proved to be generally more nimble
• The ACTIV Clinical Trials WG created “shovel-ready” network of networks for COVID trials
  • But harmonization/interoperability between networks, both within and among ICs was/is challenging
NIH Clinical Trials

• Opportunity to design and prioritize well-powered RCTs through ACTIV master protocols was crucial for rapid progress
  • Reward system in many AHCs at odds with the need to conduct larger, harmonized CT across networks to ensure adequate power
    • How to ensure appropriate “academic credit” for all involved and not just the PI?
• COVID highlighted the critical need for emphasizing diversity in trial enrollment
  • Moderna vaccine trial provided important lessons
  • But also made it clear that this capability is uneven across networks
Peer Review

• Virtual meetings are working
  • Review discussion, engaged, management, score distribution are all similar to in person meetings
  • CSR currently sees no change in reviewer diversity, but perhaps moving forward this will change
  • Recruiting members is easier

• Security matters - centralized access control/monitoring; password requirement; waiting room enabled to vet access; disabled recording/screen sharing/livestreaming/chats

• Significant cost savings

• Need a focused data-driven survey approach to supplement the current information that has been gathered
General Operations

• During a surge in demand it is critical to have a process to prioritize and manage access to limited resources
  • Project managers proved invaluable in many cases
  • The trans-NIH group, The Coronavirus Response Team, proved essential to coordinating logistical issues related to NIH Staff, space, and other logistical issues
• Communication, both internal and external, proved essential
  • Consistent, timely, tuned to the specific audiences
  • Various information portals helped inform both internal and external stakeholders
immediate challenges
Many Scientific Questions

• Vaccine hesitancy
• Additional testing paradigms
  • “At home” testing
  • Novel surveillance technologies
• Unanswered research questions – acute, short term and long-term impact of COVID-19 in different populations
• Pandemic revealed the extreme divide in health disparities – how best to redress?
Restarting Biomedical Research

• Not all research organizations and/or grantees are able to adapt to the pandemic

• Balancing funding decisions for COVID-19 needs versus overall IC mission
  • Human studies with primary data collection, the pandemic paused or stopped in-person recruitment, informed consent, interventions, and data collection.

• How best can NIH protect investments to especially at-risk groups (e.g. trainees, clinical trials, ESIs)
Peer Review

• Hybrid models should be considered
  • Alternating in-person and virtual
  • Meeting with both in-person and virtual

• Concerns and unanswered questions
  • Lost networking, especially those earlier in their career
  • Are some reviews better in-person vs virtual?
  • What is the best time format (standard full day or protracted half day – Zoom fatigue and time zone considerations)?
  • Environment, internet, and other infrastructure needs for NIH review staff, NIH program staff, and reviewers
Operational Considerations

• Evolving from a crisis response to a chronic state
• Consider need for reconfiguration of physical workspace
• Planning for the next crises
  • Emergency management center?
  • Retrospective analysis underway to inform strategic planning for next event
• Deficits due to lack of demand for fee-for-service operations
discussion

https://www.wired.com/story/wired-cartoons-week-39/